Avadel Announces New Positive Data for Once-at-Bedtime FT218 for Narcolepsy and Once-Nightly Dosing Preference Among Patients and Clinicians at World Sleep 2022
March 11, 2022 07:00 ET
|
Avadel Pharmaceuticals plc
Discrete choice experiment demonstrated that number of doses was the most important attribute driving patient and clinician preference for oxybate therapy, with once-nightly dosing strongly preferred...
Avadel Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare Conference
March 10, 2022 16:30 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, March 10, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that Greg Divis, Chief...
Avadel to Present New Clinical Data at World Sleep 2022
March 01, 2022 07:00 ET
|
Avadel Pharmaceuticals plc
Eight abstracts accepted for poster presentation featuring new data from the Phase 3 REST-ON clinical trial of FT218 and the RESTORE open-label extension/switch study of FT218 in addition to discrete...
Avadel Pharmaceuticals Appoints Dr. Douglas Williamson as Chief Medical Officer
February 14, 2022 07:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced the appointment of...
Avadel Pharmaceuticals to Present at the 11th Annual SVB Leerink Global Healthcare Conference
February 10, 2022 07:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that Greg Divis, Chief...
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
November 22, 2021 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that Greg Divis, Chief...
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences in November
November 09, 2021 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that Greg Divis, Chief...
Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2021 Financial Results
November 08, 2021 08:00 ET
|
Avadel Pharmaceuticals plc
FDA review of NDA for FT218 ongoing; commercial and launch preparations progressing Presentation of new data from pivotal REST-ON clinical trial at CHEST 2021 demonstrating that treatment...
Avadel Pharmaceuticals to Provide a Corporate Update and Report Third Quarter 2021 Financial Results on November 8th
November 01, 2021 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that it will host a...
Avadel Presents New Data Supporting Clinical Benefit with Once-at-Bedtime FT218 and Preference for Once-Nightly Dosing in Patients with Narcolepsy at CHEST 2021
October 19, 2021 08:00 ET
|
Avadel Pharmaceuticals plc
- Post-hoc responder analyses demonstrated a significantly greater proportion of patients receiving FT218 experienced reductions in weekly cataplexy attacks and improvement in mean sleep latency...